|
1
|
Yang C, Zhang H, Zhang L, Zhu AX, Bernards
R, Qin W and Wang C: Evolving therapeutic landscape of advanced
hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol.
20:203–222. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reig M, Forner A, Rimola J, Ferrer-Fàbrega
J, Burrel M, Garcia-Criado Á, Kelley RK, Galle PR, Mazzaferro V,
Salem R, et al: BCLC strategy for prognosis prediction and
treatment recommendation: The 2022 update. J Hepatol. 76:681–693.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wilhelm SM, Carter C, Tang L, Wilkie D,
McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, et al:
BAY 43-9006 exhibits broad spectrum oral antitumor activity and
targets the RAF/MEK/ERK pathway and receptor tyrosine kinases
involved in tumor progression and angiogenesis. Cancer Res.
64:7099–7109. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schroeder B, Li Z, Cranmer LD, Jones RL
and Pollack SM: Targeting gastrointestinal stromal tumors: The role
of regorafenib. Onco Targets Ther. 9:3009–3016. 2016.PubMed/NCBI
|
|
5
|
Mody K and Abou-Alfa GK: Systemic therapy
for advanced hepatocellular carcinoma in an evolving landscape.
Curr Treat Options Oncol. 20:32019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: A phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Liu S, Du Y, Ma H, Liang Q, Zhu X and Tian
J: Preclinical comparison of regorafenib and sorafenib efficacy for
hepatocellular carcinoma using multimodality molecular imaging.
Cancer Lett. 453:74–83. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Huang A, Yang XR, Chung WY, Dennison AR
and Zhou J: Targeted therapy for hepatocellular carcinoma. Signal
Transduct Target Ther. 5:1462020. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ladd AD, Duarte S, Sahin I and Zarrinpar
A: Mechanisms of drug resistance in HCC. Hepatology. 79:926–940.
2024. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhang W, Hong X, Xiao Y, Wang H and Zeng
X: Sorafenib resistance and therapeutic strategies in
hepatocellular carcinoma. Biochim Biophys Acta Rev Cancer.
1880:1893102025. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Goodman A, Patel SP and Kurzrock R:
PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas. Nat Rev
Clin Oncol. 14:203–220. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan F, Pang J, Peng Y, Molina JR, Yang P
and Liu S: Elevated cellular PD1/PD-L1 expression confers acquired
resistance to cisplatin in small cell lung cancer cells. PLoS One.
11:e01629252016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bishop JL, Sio A, Angeles A, Roberts ME,
Azad AA, Chi KN and Zoubeidi A: PD-L1 is highly expressed in
enzalutamide resistant prostate cancer. Oncotarget. 6:234–242.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Li D, Sun FF, Wang D, Wang T, Peng JJ,
Feng JQ, Li H, Wang C, Zhou DJ, Luo H, et al: Programmed death
ligand-1 (PD-L1) regulated by NRF-2/MicroRNA-1 regulatory axis
enhances drug resistance and promotes tumorigenic properties in
sorafenib-resistant hepatoma cells. Oncol Res. 28:467–481. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kikuchi H, Matsui A, Morita S, Amoozgar Z,
Inoue K, Ruan Z, Staiculescu D, Wong JSL, Huang P, Yau T, et al:
Increased CD8+ T-cell infiltration and efficacy for multikinase
inhibitors after PD-1 blockade in hepatocellular carcinoma. J Natl
Cancer Inst. 114:1301–1305. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shigeta K, Matsui A, Kikuchi H, Klein S,
Mamessier E, Chen IX, Aoki S, Kitahara S, Inoue K, Shigeta A, et
al: Regorafenib combined with PD1 blockade increases CD8 T-cell
infiltration by inducing CXCL10 expression in hepatocellular
carcinoma. J Immunother Cancer. 8:e0014352020. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li Q, Han J, Yang Y and Chen Y: PD-1/PD-L1
checkpoint inhibitors in advanced hepatocellular carcinoma
immunotherapy. Front Immunol. 13:10709612022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cayrol C and Girard JP: Interleukin-33
(IL-33): A nuclear cytokine from the IL-1 family. Immunol Rev.
281:154–168. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shlomovitz I, Erlich Z, Speir M, Zargarian
S, Baram N, Engler M, Edry-Botzer L, Munitz A, Croker BA and Gerlic
M: Necroptosis directly induces the release of full-length
biologically active IL-33 in vitro and in an inflammatory disease
model. FEBS J. 286:507–522. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cayrol C and Girard JP: IL-33: An alarmin
cytokine with crucial roles in innate immunity, inflammation and
allergy. Curr Opin Immunol. 31:31–37. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cayrol C: IL-33, an alarmin of the IL-1
family involved in allergic and non allergic inflammation: Focus on
the mechanisms of regulation of its activity. Cells. 11:1072021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Weber A, Wasiliew P and Kracht M:
Interleukin-1 (IL-1) pathway. Sci Signal. 3:cm12010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Griesenauer B and Paczesny S: The
ST2/IL-33 axis in immune cells during inflammatory diseases. Front
Immunol. 8:4752017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pisani LF, Teani I, Vecchi M and
Pastorelli L: Interleukin-33: Friend or foe in gastrointestinal
tract cancers? Cells. 12:14812023. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhao R, Yu Z, Li M and Zhou Y:
Interleukin-33/ST2 signaling promotes hepatocellular carcinoma cell
stemness expansion through activating c-Jun N-terminal kinase
pathway. Am J Med Sci. 358:279–288. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wang W, Wu J, Ji M and Wu C: Exogenous
interleukin-33 promotes hepatocellular carcinoma growth by
remodelling the tumour microenvironment. J Transl Med. 18:4772020.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yamagishi R, Kamachi F, Nakamura M,
Yamazaki S, Kamiya T, Takasugi M, Cheng Y, Nonaka Y, Yukawa-Muto Y,
Thuy LTT, et al: Gasdermin D-mediated release of IL-33 from
senescent hepatic stellate cells promotes obesity-associated
hepatocellular carcinoma. Sci Immunol. 7:eabl72092022. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang YE, Hu MH, Zeng YC, Tseng YL, Chen
YY, Su WC, Chang CP and Wang YC: IL-33/NF-κB/ST2L/Rab37
positive-feedback loop promotes M2 macrophage to limit
chemotherapeutic efficacy in lung cancer. Cell Death Dis.
15:3562024. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen SH, Hu CP, Lee CK and Chang C: Immune
reactions against hepatitis B viral antigens lead to the rejection
of hepatocellular carcinoma in BALB/c mice. Cancer Res.
53:4648–4651. 1993.PubMed/NCBI
|
|
30
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q,
Li B and Liu XS: TIMER2.0 for analysis of tumor-infiltrating immune
cells. Nucleic Acids Res 48 (W1). W509–W514. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pan X, Liu J, Li M, Liang Y, Liu Z, Lao M
and Fang M: The association of serum IL-33/ST2 expression with
hepatocellular carcinoma. BMC Cancer. 23:7042023. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Akimoto M, Hayashi JI, Nakae S, Saito H
and Takenaga K: Interleukin-33 enhances programmed oncosis of
ST2L-positive low-metastatic cells in the tumour microenvironment
of lung cancer. Cell Death Dis. 7:e20572016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wang C, Wang H, Lieftink C, du Chatinier
A, Gao D, Jin G, Jin H, Beijersbergen RL, Qin W and Bernards R:
CDK12 inhibition mediates DNA damage and is synergistic with
sorafenib treatment in hepatocellular carcinoma. Gut. 69:727–736.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Roger L, Tomas F and Gire V: Mechanisms
and regulation of cellular senescence. Int J Mol Sci. 22:131732021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhao M, He Y, Zhu N, Song Y, Hu Q, Wang Z,
Ni Y and Ding L: IL-33/ST2 signaling promotes constitutive and
inductive PD-L1 expression and immune escape in oral squamous cell
carcinoma. Br J Cancer. 128:833–843. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong
W, Yi M and Xiang B: Regulatory mechanisms of PD-1/PD-L1 in
cancers. Mol Cancer. 23:1082024. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Jian C, Fu J, Cheng X, Shen LJ, Ji YX,
Wang X, Pan S, Tian H, Tian S, Liao R, et al: Low-dose sorafenib
acts as a mitochondrial uncoupler and ameliorates nonalcoholic
steatohepatitis. Cell Metab. 31:12062020. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Shiau DJ, Kuo WT, Davuluri GVN, Shieh CC,
Tsai PJ, Chen CC, Lin YS, Wu YZ, Hsiao YP and Chang CP:
Hepatocellular carcinoma-derived high mobility group box 1 triggers
M2 macrophage polarization via a TLR2/NOX2/autophagy axis. Sci Rep.
10:135822020. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kudo-Saito C, Miyamoto T, Imazeki H, Shoji
H, Aoki K and Boku N: IL33 is a key driver of treatment resistance
of cancer. Cancer Res. 80:1981–1990. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Luo H, Liu L, Liu X, Xie Y, Huang X, Yang
M, Shao C and Li D: Interleukin-33 (IL-33) promotes DNA
damage-resistance in lung cancer. Cell Death Dis. 16:2742025.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Katz-Kiriakos E, Steinberg DF, Kluender
CE, Osorio OA, Newsom-Stewart C, Baronia A, Byers DE, Holtzman MJ,
Katafiasz D, Bailey KL, et al: Epithelial IL-33 appropriates
exosome trafficking for secretion in chronic airway disease. JCI
Insight. 6:e1361662021.PubMed/NCBI
|
|
43
|
Chen W, Chen S, Yan C, Zhang Y, Zhang R,
Chen M, Zhong S, Fan W, Zhu S, Zhang D, et al: Allergen
protease-activated stress granule assembly and gasdermin D
fragmentation control interleukin-33 secretion. Nat Immunol.
23:1021–1030. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Dong Z, Luo Y, Yuan Z, Tian Y, Jin T and
Xu F: Cellular senescence and SASP in tumor progression and
therapeutic opportunities. Mol Cancer. 23:1812024. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Liu G, Chen Y, Dai S, Wu G, Wang F, Chen
W, Wu L, Luo P and Shi C: Targeting the NLRP3 in macrophages
contributes to senescence cell clearance in radiation-induced skin
injury. J Transl Med. 23:1962025. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chen L, Gao C, Yin X, Mo L, Cheng X, Chen
H, Jiang C, Wu B, Zhao Y, Li H, et al: Partial reduction of
interleukin-33 signaling improves senescence and renal injury in
diabetic nephropathy. MedComm (2020). 5:e7422024. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Zhang J, Zhao X, Ma X, Yuan Z and Hu M:
KCNQ1OT1 contributes to sorafenib resistance and programmed
death-ligand-1-mediated immune escape via sponging miR-506 in
hepatocellular carcinoma cells. Int J Mol Med. 46:1794–1804.
2020.PubMed/NCBI
|
|
48
|
Xu R, Liu X, Li A, Song L, Liang J, Gao J
and Tang X: c-Met up-regulates the expression of PD-L1 through
MAPK/NF-κBp65 pathway. J Mol Med (Berl). 100:585–598. 2022.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Liu J, Liu Y, Meng L, Liu K and Ji B:
Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib
in human hepatocellular carcinoma. Oncol Rep. 38:899–907. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Xu GL, Ni CF, Liang HS, Xu YH, Wang WS,
Shen J, Li MM and Zhu XL: Upregulation of PD-L1 expression promotes
epithelial-to-mesenchymal transition in sorafenib-resistant
hepatocellular carcinoma cells. Gastroenterol Rep (Oxf). 8:390–398.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Shrestha R, Prithviraj P, Bridle KR,
Crawford DHG and Jayachandran A: Combined inhibition of
TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular
carcinoma to sorafenib treatment. J Clin Med. 10:18892021.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Qin L, Dominguez D, Chen S, Fan J, Long A,
Zhang M, Fang D, Zhang Y, Kuzel TM and Zhang B: Exogenous IL-33
overcomes T cell tolerance in murine acute myeloid leukemia.
Oncotarget. 7:61069–61080. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Cui G, Qi H, Gundersen MD, Yang H,
Christiansen I, Sørbye SW, Goll R and Florholmen J: Dynamics of the
IL-33/ST2 network in the progression of human colorectal adenoma to
sporadic colorectal cancer. Cancer Immunol Immunother. 64:181–190.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Shani O, Vorobyov T, Monteran L, Lavie D,
Cohen N, Raz Y, Tsarfaty G, Avivi C, Barshack I and Erez N:
Fibroblast-derived IL33 Facilitates breast cancer metastasis by
modifying the immune microenvironment and driving type 2 immunity.
Cancer Res. 80:5317–5329. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Yeoh WJ, Vu VP and Krebs P: IL-33 biology
in cancer: An update and future perspectives. Cytokine.
157:1559612022. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Yang Q, Cui M, Wang J, Zhao Y, Yin W, Liao
Z, Liang Y, Jiang Z, Li Y, Guo J, et al: Circulating mitochondrial
DNA promotes M2 polarization of tumor associated macrophages and
HCC resistance to sorafenib. Cell Death Dis. 16:1532025. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Shen Y, Wang H, Ma Z, Hao M, Wang S, Li J,
Fang Y, Yu L, Huang Y, Wang C, et al: Sorafenib promotes treg cell
differentiation to compromise its efficacy via VEGFR/AKT/Foxo1
signaling in hepatocellular carcinoma. Cell Mol Gastroenterol
Hepatol. 19:1014542025. View Article : Google Scholar : PubMed/NCBI
|
